{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:47:21Z","timestamp":1765540041139,"version":"3.48.0"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jcim-2023-0235_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      Preclinical evidence is needed to assess drug-metabolite behaviour in compromised liver function for developing the best antitubercular treatment (ATT) re-introduction regimen in drug-induced liver injury (DILI). The pharmacokinetic behavior of rifampicin (RMP) and its active metabolite des-acetyl-rifampicin (DARP) in DILI\u2019s presence is unknown. To study the pharmacokinetic behavior of RMP and DARP in the presence of carbon tetrachloride (CCl\n                      <jats:sub>4<\/jats:sub>\n                      ) plus ATT-DILI in rats.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2023-0235_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Thirty rats used in the experiment were divided equally into six groups. We administered a single 0.5\u202fmL\/kg CCl\n                      <jats:sub>4<\/jats:sub>\n                      intraperitoneal injection in all rats. Groups II, III, IV, and V were started on daily oral RMP alone, RMP plus isoniazid (INH), RMP plus pyrazinamide (PZA), and the three drugs INH, RMP, and PZA together, respectively, for 21-days subsequently. Pharmacokinetic (PK) sampling was performed at 0, 0.5, 1, 3, 6, 12, and 24\u202fh post-dosing on day 20. We monitored LFT at baseline on days-1, 7, and 21 and sacrificed the rats on the last day of the experiment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2023-0235_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ATT treatment sustained the CCl\n                      <jats:sub>4<\/jats:sub>\n                      -induced liver injury changes. A significant rise in mean total bilirubin levels was observed in groups administered rifampicin. The triple drug combination group demonstrated 1.43- and 1.84-times higher area-under-the-curve values of RMP (234.56\u00b130.66 vs. 163.55\u00b136.14\u202f\u00b5g\u202fh\/mL) and DARP (16.15\u00b14.50 vs. 8.75\u00b12.79\u202f\u00b5g\u202fh\/mL) compared to RMP alone group. Histological and oxidative stress changes supported underlying liver injury and PK alterations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2023-0235_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RMP metabolism inhibition by PZA, more than isoniazid, was well preserved in the presence of underlying liver injury.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jcim-2023-0235","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T02:40:25Z","timestamp":1703299225000},"page":"38-45","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic assessment of rifampicin and des-acetyl rifampicin in carbon tetrachloride induced liver injury model in Wistar rats"],"prefix":"10.1515","volume":"21","author":[{"given":"Swati","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine and Biotechnology , Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aishwarya","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Taneja","sequence":"additional","affiliation":[{"name":"Department of Hepatology , Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology , Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alka","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine and Biotechnology , Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8552-2796","authenticated-orcid":false,"given":"Amol N.","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Pharmacology , Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh , India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dibyajyoti","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine and Biotechnology , Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh , India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,12,25]]},"reference":[{"key":"2025121209103266815_j_jcim-2023-0235_ref_001","doi-asserted-by":"crossref","unstructured":"Prasad, R, Gupta, N, Banka, A. Multidrug-resistant tuberculosis\/rifampicin-resistant tuberculosis: principles of management. Lung India Off Organ Indian Chest Soc 2018;35:78\u201381. https:\/\/doi.org\/10.4103\/lungindia.lungindia_98_17.","DOI":"10.4103\/lungindia.lungindia_98_17"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_002","unstructured":"Thakur, G, Thakur, S, Thakur, H. Status and challenges for tuberculosis control in India\u00a0\u2013 stakeholders\u2019 perspective. Indian J Tuberc [Internet] 2020. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7550054\/ [Accessed 15 Feb 2023]."},{"key":"2025121209103266815_j_jcim-2023-0235_ref_003","doi-asserted-by":"crossref","unstructured":"Nunn, AJ, Rusen, I, Van Deun, A, Torrea, G, Phillips, PP, Chiang, CY, et al.. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials 2014;15:353. https:\/\/doi.org\/10.1186\/1745-6215-15-353.","DOI":"10.1186\/1745-6215-15-353"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_004","doi-asserted-by":"crossref","unstructured":"Sloan, DJ, Davies, GR, Khoo, SH. Recent advances in tuberculosis: new drugs and treatment regimens. Curr Respir Med Rev 2013;9:200\u201310. https:\/\/doi.org\/10.2174\/1573398x113099990017.","DOI":"10.2174\/1573398X113099990017"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_005","doi-asserted-by":"crossref","unstructured":"Raj Mani, SS, Iyyadurai, R, Mishra, AK, Manjunath, K, Prasad, J, Lakshmanan, J, et al.. Predicting antitubercular drug-induced liver injury and its outcome and introducing a novel scoring system. Int J Mycobacteriol 2021;10:116\u201321. https:\/\/doi.org\/10.4103\/ijmy.ijmy_15_21.","DOI":"10.4103\/ijmy.ijmy_15_21"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_006","doi-asserted-by":"crossref","unstructured":"Bekker, A, Schaaf, HS, Draper, HR, van der Laan, L, Murray, S, Wiesner, L, et al.. Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines. Antimicrob Agents Chemother 2016;60:2171\u20139. https:\/\/doi.org\/10.1128\/aac.02600-15.","DOI":"10.1128\/AAC.02600-15"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_007","doi-asserted-by":"crossref","unstructured":"Burhan, E, Ruesen, C, Ruslami, R, Ginanjar, A, Mangunnegoro, H, Ascobat, P, et al.. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob Agents Chemother 2013;57:3614\u20139. https:\/\/doi.org\/10.1128\/aac.02468-12.","DOI":"10.1128\/AAC.02468-12"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_008","doi-asserted-by":"crossref","unstructured":"Thee, S, Seddon, JA, Donald, PR, Seifart, HI, Werely, CJ, Hesseling, AC, et al.. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World health Organization recommendations. Antimicrob Agents Chemother. 2011;55:5560\u20137, https:\/\/doi.org\/10.1128\/aac.05429-11.","DOI":"10.1128\/AAC.05429-11"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_009","doi-asserted-by":"crossref","unstructured":"Mukherjee, A, Lodha, R, Kabra, SK. Pharmacokinetics of first-line anti-tubercular drugs. Indian J Pediatr 2019;86:468\u201378. https:\/\/doi.org\/10.1007\/s12098-019-02911-w.","DOI":"10.1007\/s12098-019-02911-w"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_010","doi-asserted-by":"crossref","unstructured":"Sharma, SK, Singla, R, Sarda, P, Mohan, A, Makharia, G, Jayaswal, A, et al.. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis Off Publ Infect Dis Soc Am 2010;50:833\u20139. https:\/\/doi.org\/10.1086\/650576.","DOI":"10.1086\/650576"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_011","unstructured":"Frontiers|Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: a review [Internet]. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1037814\/full [Accessed 15 Feb 2023]."},{"key":"2025121209103266815_j_jcim-2023-0235_ref_012","doi-asserted-by":"crossref","unstructured":"Patil, AN, Kasudhan, KS, Naveen, M, Batra, GK, Chakrabarti, S, Avasthi, A, et al.. Precise pharmacogenetic pharmacometabolomic (PPP) guided clozapine therapy in treatment resistant schizophrenia: insights from one ethnicity experiment. Schizophr Res 2021;237:26\u20138. https:\/\/doi.org\/10.1016\/j.schres.2021.08.016.","DOI":"10.1016\/j.schres.2021.08.016"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_013","doi-asserted-by":"crossref","unstructured":"Niemi, M, Backman, JT, Fromm, MF, Neuvonen, PJ, Kivist\u00f6, KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42:819\u201350. https:\/\/doi.org\/10.2165\/00003088-200342090-00003.","DOI":"10.2165\/00003088-200342090-00003"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_014","doi-asserted-by":"crossref","unstructured":"Chik, Z, Basu, RC, Pendek, R, Lee, TC, Mohamed, Z. A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): an open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. Clin Therapeut 2010;32:1822\u201331. https:\/\/doi.org\/10.1016\/j.clinthera.2010.09.006.","DOI":"10.1016\/j.clinthera.2010.09.006"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_015","doi-asserted-by":"crossref","unstructured":"Su, Q, Liu, Q, Liu, J, Fu, L, Liu, T, Liang, J, et al.. Study on the associations between liver damage and antituberculosis drug rifampicin and relative metabolic enzyme gene polymorphisms. Bioengineered;12:11700\u20138. https:\/\/doi.org\/10.1080\/21655979.2021.2003930.","DOI":"10.1080\/21655979.2021.2003930"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_016","doi-asserted-by":"crossref","unstructured":"Soni, H, Kumar, -MP, Mishra, S, Bellam, BL, Singh, H, Mandavdhare, HS, et al.. Risk of hepatitis with various reintroduction regimens of anti-tubercular therapy: a systematic review and network meta-analysis. Expert Rev Anti Infect Ther 2020;18:171\u20139. https:\/\/doi.org\/10.1080\/14787210.2020.1714436.","DOI":"10.1080\/14787210.2020.1714436"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_017","doi-asserted-by":"crossref","unstructured":"Attri, S, Rana, SV, Vaiphei, K, Sodhi, CP, Katyal, R, Goel, RC, et al.. Isoniazid- and rifampicin-induced oxidative hepatic injury\u00a0\u2013 protection by N-acetylcysteine. Hum Exp Toxicol 2000;19:517\u201322. https:\/\/doi.org\/10.1191\/096032700674230830.","DOI":"10.1191\/096032700674230830"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_018","doi-asserted-by":"crossref","unstructured":"Ruan, LY, Fan, JT, Hong, W, Zhao, H, Li, MH, Jiang, L, et al.. Isoniazid-induced hepatotoxicity and neurotoxicity in rats investigated by 1H NMR based metabolomics approach. Toxicol Lett 2018;295:256\u201369. https:\/\/doi.org\/10.1016\/j.toxlet.2018.05.032.","DOI":"10.1016\/j.toxlet.2018.05.032"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_019","doi-asserted-by":"crossref","unstructured":"Naik, SR, Panda, VS. Hepatoprotective effect of Ginkgoselect Phytosome in rifampicin induced liver injury in rats: evidence of antioxidant activity. Fitoterapia 2008;79:439\u201345. https:\/\/doi.org\/10.1016\/j.fitote.2008.02.013.","DOI":"10.1016\/j.fitote.2008.02.013"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_020","doi-asserted-by":"crossref","unstructured":"Kovalenko, VM, Bagnyukova, TV, Sergienko, OV, Bondarenko, L, Shayakhmetova, G, Matvienko, A, et al.. Epigenetic changes in the rat livers induced by pyrazinamide treatment. Toxicol Appl Pharmacol 2007;225:293\u20139. https:\/\/doi.org\/10.1016\/j.taap.2007.08.011.","DOI":"10.1016\/j.taap.2007.08.011"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_021","doi-asserted-by":"crossref","unstructured":"Sharma, S, Anand, A, Bhatia, A, Sharma, V, Singh, AK, Banerjee, D, et al.. Pharmacological evaluation of Scopoletin in the carbon tetrachloride-induced hepatotoxicity model in Wistar rats. J Pharm BioAllied Sci 2022;14:201\u20136. https:\/\/doi.org\/10.4103\/jpbs.jpbs_333_22.","DOI":"10.4103\/jpbs.jpbs_333_22"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_022","doi-asserted-by":"crossref","unstructured":"Gorski, JC, Vannaprasaht, S, Hamman, MA, Ambrosius, WT, Bruce, MA, Haehner-Daniels, B, et al.. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol The. 2003;74:275\u201387. https:\/\/doi.org\/10.1016\/S0009-9236(03)00187-5.","DOI":"10.1016\/S0009-9236(03)00187-5"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_023","doi-asserted-by":"crossref","unstructured":"Choi, R, Jeong, BH, Koh, WJ, Lee, SY. Recommendations for optimizing tuberculosis treatment: therapeutic drug monitoring, pharmacogenetics, and nutritional Status considerations. Ann Lab Med 2017;37:97\u2013107. https:\/\/doi.org\/10.3343\/alm.2017.37.2.97.","DOI":"10.3343\/alm.2017.37.2.97"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_024","doi-asserted-by":"crossref","unstructured":"Peloquin, CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002;62:2169\u201383. https:\/\/doi.org\/10.2165\/00003495-200262150-00001.","DOI":"10.2165\/00003495-200262150-00001"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_025","doi-asserted-by":"crossref","unstructured":"van Beek, SW, Ter Heine, R, Keizer, RJ, Magis-Escurra, C, Aarnoutse, RE, Svensson, EM. Personalized tuberculosis treatment through model-informed dosing of rifampicin. Clin Pharmacokinet 2019;58:815\u201326. https:\/\/doi.org\/10.1007\/s40262-018-00732-2.","DOI":"10.1007\/s40262-018-00732-2"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_026","doi-asserted-by":"crossref","unstructured":"Svensson, RJ, Niward, K, Davies Forsman, L, Bruchfeld, J, Paues, J, Eliasson, E, et al.. Individualised dosing algorithm and personalised treatment of high\u2010dose rifampicin for tuberculosis. Br J Clin Pharmacol 2019;85:2341\u201350. https:\/\/doi.org\/10.1111\/bcp.14048.","DOI":"10.1111\/bcp.14048"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_027","doi-asserted-by":"crossref","unstructured":"Grover, S, Kasudhan, KS, Murali, N, Patil, AN, Pattanaik, S, Chakrabarti, S, et al.. Pharmacometabolomics-guided clozapine therapy in treatment resistant schizophrenia: preliminary exploration of future too near. Asian J Psychiatry 2022;67:102939. https:\/\/doi.org\/10.1016\/j.ajp.2021.102939.","DOI":"10.1016\/j.ajp.2021.102939"},{"key":"2025121209103266815_j_jcim-2023-0235_ref_028","doi-asserted-by":"crossref","unstructured":"Kasudhan, KS, Patil, AN, Jandial, A, Khadwal, A, Prakash, G, Jain, A, et al.. Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study. Leuk Lymphoma 2022;63:2679\u201385. https:\/\/doi.org\/10.1080\/10428194.2022.2087067.","DOI":"10.1080\/10428194.2022.2087067"}],"container-title":["Journal of Complementary and Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2023-0235\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2023-0235\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:43:06Z","timestamp":1765539786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2023-0235\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,25]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,10]]},"published-print":{"date-parts":[[2024,3,20]]}},"alternative-id":["10.1515\/jcim-2023-0235"],"URL":"https:\/\/doi.org\/10.1515\/jcim-2023-0235","relation":{},"ISSN":["1553-3840"],"issn-type":[{"type":"electronic","value":"1553-3840"}],"subject":[],"published":{"date-parts":[[2023,12,25]]}}}